• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Mechanism of development of resistance to antitumor molecule-targeted drugs

Research Project

Project/Area Number 18K06743
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 47060:Clinical pharmacy-related
Research InstitutionGunma University

Principal Investigator

Araki Takuya  群馬大学, 大学院医学系研究科, 准教授 (00568248)

Co-Investigator(Kenkyū-buntansha) 八島 秀明  群馬大学, 医学部附属病院, 助教 (60773512)
山本 康次郎  群馬大学, 大学院医学系研究科, 教授 (70174787)
永野 大輔  群馬大学, 大学院医学系研究科, 助教 (90738387)
Project Period (FY) 2018-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords薬剤抵抗性 / 分子標的薬 / 抗体医薬品 / がん / 化学療法 / 獲得耐性 / 抗腫瘍薬 / プロテオーム / 抗体医薬 / 薬物抵抗性
Outline of Final Research Achievements

In this study, we detected multiple proteins and signaling pathways that are thought to be involved in developing the resistance to molecular-targeted drugs. As a result of analyzing some candidates as the primary targets, it was shown that drug resistance could be released by regulating some of those proteins. Furthermore, some of these candidates can be regulated by the drugs used to treat other diseases.
These results indicated that there is a possibility that drug resistance can be released by using existing drugs well.
By expanding the research method used in this study, it is possible to elucidate the factors of resistance to molecular-targeted drugs, and it is expected that it will lead to the construction of a method for releasing drug resistance.

Academic Significance and Societal Importance of the Research Achievements

本研究によってがん治療に用いる分子標的薬に対する抵抗性獲得機構の一部が明らかになり、同手法を用いることによって薬剤抵抗性を解除するための方法を構築できる可能性があることが示された。本研究手法は様々な薬剤に対する抵抗性獲得機構の解明に応用できることから、本研究で得られた知見はがん治療の大きな発展に寄与しうるものである。効果が高い既存薬を適切に扱うことにより、現在のがん化学療法の効果を大幅に改善できる可能性を示したものであり、その社会的意義は大きいと考えられる。

Report

(5 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Research-status Report
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (4 results)

All 2019 2018

All Journal Article (2 results) (of which Peer Reviewed: 2 results) Presentation (2 results)

  • [Journal Article] L-Lactate dehydrogenase B may be a predictive marker for sensitivity to anti-EGFR monoclonal antibodies in colorectal cancer cell lines2019

    • Author(s)
      Ayumu Nagamine, Takuya Araki, Daisuke Nagano, Mitsue Miyazaki, Koujirou Yamamoto
    • Journal Title

      Oncology letters

      Volume: 17 Pages: 4710-4716

    • DOI

      10.3892/ol.2019.10075

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] Exploration of proteins involved in acquisition of resistance to cetuximab2019

    • Author(s)
      Hironori Nakamura, Ayumu Nagamine, Hideaki Yashima, Takuya Araki, Koujirou Yamamoto
    • Journal Title

      Indonesian Journal of Pharmaceutics

      Volume: 1 Issue: 1 Pages: 11-18

    • DOI

      10.24198/idjp.v1i1.19582

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Presentation] セツキシマブに対する後天的耐性を獲得した大腸癌に対する治療法の探索2019

    • Author(s)
      荒木拓也, 中村浩規, 長嶺歩, 八島秀明, 山本康次郎
    • Organizer
      第29回日本医療薬学会年会
    • Related Report
      2019 Research-status Report
  • [Presentation] ヒト大腸癌細胞株に対するセツキシマブの効果と LDH 発現量の関係2018

    • Author(s)
      長嶺歩,荒木拓也,永野大輔,山本康次郎
    • Organizer
      医療薬学フォーラム2018・第26回クリニカルファーマシーシンポジウム
    • Related Report
      2018 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi